Assembly Biosciences Inc (ASMB) Q2 2015 10-Q Quarterly Earnings

Short answer

Assembly Biosciences Inc (ASMB) filed its Q2 2015 10-Q quarterly report on Aug 13, 2015 for the quarter ended Jun 30, 2015.

AI summary of MD&A and risk factor updates

Revenue $0, unchanged YoY, with no product sales since inception
Operating margin unavailable, quarterly R&D expense $4.7M vs $1.1M YoY
HBV program strongest growth, R&D increase $2.5M for the quarter
Operating cash use $8.1M, investing cash use $48.8M, financing cash provided $81.3M
$81.0M equity proceeds, cash expected to fund operations for at least twelve months, future losses anticipated

Newly triggered risk: HBV program launched July 2014, increasing research expenses $4,370,026 year-to-date
Most materially updated risk: CEO succession triggered former CEO termination benefits, including 12 months’ salary and accelerated option vesting
Regulatory risk: No FDA-approved products or product revenue, with future commercialization dependent on regulatory approval
Operational risk: Continued development of HBV and microbiome programs expected to drive increasing research and development expenses
Financial risk: $8,056,007 operating cash use in six months, requiring additional funding despite liquidity for at least twelve months

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Compare quarters, check guidance or see what insiders and funds did around the report.